Hugel Inc (145020) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Hugel Inc KRW 283,308, price KRW 187,000, upside +51.5%, quality 80 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hugel Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally.
Show more
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
Stock analysis
Hugel Inc (145020) currently trades at 187,000 KRW, while our model-based Fair Value estimate is 283,308 KRW, implying the stock looks roughly 34.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 312,086 KRW per share, and 19 of the 24 models we run sit above the 187,000 KRW price.
Bear case: the Asset-Based group reads lowest at 58,933 KRW, and 5 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 182,694 KRW (bear) to 405,711 KRW (bull), the price of 187,000 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Hugel Inc reported revenue of 425B KRW in FY2025 versus 245B KRW in FY2021, a compound +14.8%/yr. Reported net income was 141B KRW in FY2025, compounding +25.0%/yr from FY2021.
Key figures
Market cap 2.6T KRW (≈ $1.8B) · P/S ratio 5.71 · Net margin 33.1% · Return on equity 16.4% · Return on assets (EBIT) 12.9% · Operating margin 40.8% · Revenue (TTM) 452B KRW · Revenue growth (YoY) +29.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 52%, 145020 screens cheaper than that median.
Fair Value models
Bear 182,694 KRWFair Value 283,308 KRWBull 405,711 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Start year 2020 (pandemic). Over 10 years: +20.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+35.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+35.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.30% vs 11%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.37% → 47%
2025 sits 57% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +1.6% a year for the price and +16.1% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 9/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score80 · Top 25%
Fair Value upside+67% · Top 25%
Profitability
Return on equity (TTM)16% · Top 25%
Return on assets12% · Top 25%
Net margin (TTM)33% · Top 25%
Operating margin (TTM)41% · Top 25%
Growth and dividend
Revenue growth30% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hugel Inc Fair Value". https://www.fairvalue-calculator.com/stock/145020
Frequently asked questions
Is Hugel Inc (145020) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 283,308 KRW versus a price of 187,000 KRW, about +52% upside (undervalued).
What is the fair value of 145020?
Our model-based fair value for Hugel Inc is 283,308 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 187,000 KRW.
What is the quality score of 145020?
Hugel Inc has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hugel Inc (145020)?
Our model-based price target is the fair value of 283,308 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 182,694 KRW, optimistic scenario 405,711 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Hugel Inc stock forecast for 2026?
Our models put fair value at 283,308 KRW, about +52% upside versus a price of 187,000 KRW (undervalued). Cautious scenario 182,694 KRW, optimistic scenario 405,711 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Hugel Inc (145020)?
Hugel Inc reported trailing-twelve-month revenue of about 452B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into Hugel Inc (145020)?
For today's price to be fair in a discounted-cash-flow model, Hugel Inc would have to grow free cash flow by +3.7 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 145020 use?
Our models discount Hugel Inc at 10.2 %: a base by market capitalisation (small), damped by beta 0.50, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hugel Inc that is +3.7 % per year a year over ten years, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Hugel Inc (145020) delivered so far?
Over the past 5 years revenue at Hugel Inc grew +15.0 % a year. The price currently implies +3.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hugel Inc (145020) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Hugel Inc (+3.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hugel Inc (145020)?
The free-cash-flow yield on the price is 5.97 %: that much free cash flow Hugel Inc produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hugel Inc (145020)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hugel Inc it is 283,308 KRW per share (as of Sep 24, 2026), against a price of 187,000 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Hugel Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 145020 trades below its calculated fair value: price 187,000 KRW, fair value 283,308 KRW, a gap of about +52% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 145020?
No. The price is what the market pays today (187,000 KRW); the fair value is what the company's own numbers justify (283,308 KRW). For Hugel Inc the two are 96,308 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Hugel Inc worth?
The market values Hugel Inc at about 2.6T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 187,000 KRW; our models calculate a fair value of 283,308 KRW per share.
What do the bullish and bearish scenarios say about 145020?
Our models span a range for Hugel Inc: cautious scenario 182,694 KRW, base 283,308 KRW, optimistic 405,711 KRW per share (as of Sep 24, 2026, price 187,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hugel Inc (145020)?
Balance-sheet figures for Hugel Inc (as of Sep 24, 2026): return on equity 16.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 80/100, which measures business quality independently of the share price.
How far is 145020 from its 52-week high?
Hugel Inc trades at 187,000 KRW, about 39% below its 52-week high of 307,000 KRW and at the low of 187,000 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 283,308 KRW is for.
Which stocks are comparable to Hugel Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hugel Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 187,000 KRW, calculated fair value 283,308 KRW (+52%), Quality Score 80/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 145020 calculated?
We run Hugel Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 283,308 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Hugel Inc currently trades 52 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hugel Inc (145020)?
The closing price on Sep 23, 2026 was 187,000 KRW. Our model-based fair value is 283,308 KRW, about +52% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hugel Inc right now?
The rarer combination: high quality (80/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range (182,694 KRW to 405,711 KRW) leaves room in how you read the outcome.
Key figures of Hugel Inc
How large is the market capitalisation of Hugel Inc (145020)?
The market capitalisation of Hugel Inc is 2.6T KRW (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hugel Inc (145020)?
The price-to-sales ratio of Hugel Inc is 5.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Hugel Inc (145020)?
The net margin of Hugel Inc is 33.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hugel Inc (145020)?
The return on equity (ROE) of Hugel Inc is 16.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hugel Inc (145020)?
On an EBIT basis the return on assets of Hugel Inc is 12.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hugel Inc (145020)?
The operating margin of Hugel Inc is 40.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hugel Inc (145020)?
Revenue at Hugel Inc is growing +29.9% versus a year earlier (3y avg +14.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hugel Inc (145020)?
Earnings per share at Hugel Inc are growing +35.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hugel Inc (145020) carry?
The net debt of Hugel Inc is 27.7B KRW (fiscal year 2020, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hugel Inc in the live analysis
One click puts Hugel Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
